Moreover, research indicates that PQQ exhibits significant antioxidant properties. It helps to neutralize free radicals, thus reducing oxidative stress in the body. Oxidative stress has been implicated in various health issues, including neurodegenerative diseases, cardiovascular problems, and aging. By mitigating this stress, PQQ supports overall cellular health and longevity.
After successful preclinical trials, the API enters clinical development, where it is tested in a series of progressively larger phases in human subjects. Each phase is designed to gather more data about the drug's safety and effectiveness. Depending on the results of these studies, the drug may eventually receive approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), paving the way for commercial production.
api drug substance